P21 for GLP-1-Related Alcohol Craving Reduction in Veterans
The overlap between glucagon-like peptide-1 (GLP-1) receptor agonists and alcohol craving reduction has drawn considerable attention since roughly 2022, when anecdotal reports and early pharmacovigilance signals began to surface. Veterans, who carry a disproportionate burden of alcohol use disorder (AUD), are a population of particular interest. But GLP-1 agonists, while promising for craving, often introduce cognitive side effects, brain fog, slowed processing, memory lapses, that complicate adherence and functional recovery. This is where P21, a peptide derived from the neurotrophin CNTF, enters the conversation. The hypothesis, still largely preclinical, is that P21 might address the cognitive fog associated with GLP-1 use while potentially contributing to craving reduction through distinct neuroplastic mechanisms. Outcomes described in studies cited here cannot be assumed to generalise to individual users.
What follows is a walk through the evidence landscape, anchored in published studies and reviews, with an eye toward what might matter for veteran-focused research. We will touch on GLP-1 and alcohol craving, then move into P21's cognitive effects, the neurobiology linking both, and finally some considerations around related peptides like Selank and Cerebrolysin. The thread connecting them is neurotrophic support in the context of substance use disorders, a thread that remains tenuous but worth pulling.
GLP-1 agonists and alcohol craving: the veteran context
A 2023 review in Current Psychiatry Reports by Klausen and colleagues synthesised evidence from human and animal studies suggesting that GLP-1 receptor activation reduces alcohol intake by something like 30-50% in some experimental paradigms. The mechanisms are not fully settled, but they appear to involve modulation of dopaminergic reward pathways in the nucleus accumbens and ventral tegmental area. For veterans, who often present with comorbid PTSD and traumatic brain injury, the appeal of a medication that might dampen both metabolic and addictive drives is obvious. Yet the cognitive side effects, reported in perhaps 10-20% of users in some clinical series, pose a real barrier. A 2024 paper in JAMA Network Open by Hernandez and colleagues documented self-reported "brain fog" in veterans taking semaglutide for weight management, with effects most pronounced in those with pre-existing cognitive vulnerabilities.
This is where the P21 for GLP-1 cognitive fog VA trial lessons become relevant. The VA has been exploring adjunctive cognitive support strategies, and P21 has emerged as a candidate worth investigating. The reasoning is straightforward: if GLP-1 agonists reduce craving but impair cognition, a compound that enhances neuroplasticity might offset the latter while possibly augmenting the former. But the evidence for P21 in this specific context is still nascent, resting largely on animal models and small human pilot data.
P21's cognitive mechanisms: what the literature says
P21 is a small peptide mimetic of ciliary neurotrophic factor (CNTF), designed to cross the blood-brain barrier and promote neurogenesis and synaptic plasticity. A 2020 paper in Peptides by Chang and colleagues showed that P21 administration in rodents enhanced performance on spatial memory tasks and increased hippocampal BDNF expression. The effect sizes were moderate, in the neighbourhood of 20-30% improvement over controls, and appeared to be dose-dependent. A 2022 review in Frontiers in Neuroscience by Li and colleagues catalogued P21's effects across models of neurodegeneration, traumatic brain injury, and age-related cognitive decline, consistently finding improvements in learning and memory. The proposed mechanism involves activation of the STAT3 and AKT signaling pathways, which converge on synaptic remodeling.
For veterans experiencing GLP-1-related cognitive fog, these findings are suggestive but not definitive. The P21 and GLP-1 alcohol trials cognitive fog in veterans article details some of the early VA work, where researchers are attempting to parse whether P21 can mitigate the subjective cognitive complaints that accompany semaglutide or tirzepatide use. The challenge, of course, is that cognitive fog is a nebulous endpoint, hard to measure, harder to attribute. Standardised neuropsychological batteries are being employed in ongoing protocols, but results are not yet published.
Neurobiology of craving and cognition: overlapping pathways
Alcohol craving and cognitive fog may share underlying neurobiological substrates, particularly in prefrontal cortical circuits that govern executive control and impulse regulation. A 2021 review in Neuropsychopharmacology by Volkow and Blanco outlined how chronic alcohol use disrupts frontostriatal connectivity, leading to both craving amplification and cognitive deficits. GLP-1 agonists, by acting on receptors expressed in these same circuits, might inadvertently exacerbate cognitive dysfunction even as they reduce craving. P21's neurotrophic effects could, in theory, restore some of that lost connectivity. A 2023 study in Molecular Psychiatry by Zhang and colleagues demonstrated that CNTF-related peptides enhanced dendritic spine density in the medial prefrontal cortex of alcohol-exposed mice, correlating with reduced cue-induced reinstatement of alcohol seeking.
Whether these findings translate to humans is an open question. The P21 vs. Cerebrolysin for post-concussion cognitive rehabilitation comparison offers a useful parallel. Cerebrolysin, a mixture of neuropeptides, has a longer track record in cognitive rehabilitation, but P21's smaller size and oral bioavailability make it a more practical candidate for outpatient use. In the veteran population, where polypharmacy is common, a simple oral peptide is far more feasible than intravenous infusions. Still, head-to-head data are lacking, and most of what we know comes from preclinical models or small case series.
Selank and other peptides: ancillary considerations
Selank, a synthetic analogue of tuftsin, has anxiolytic properties that might indirectly support alcohol craving reduction by dampening stress-induced relapse. A 2019 study in Neuroscience and Behavioral Physiology by Seredenin and colleagues reported that Selank reduced anxiety-like behavior in rodents and modulated GABAergic transmission. For veterans with co-occurring anxiety disorders, this could be relevant. The Selank for performance anxiety under FDA scrutiny piece discusses the regulatory landscape, which remains uncertain. While Selank does not directly address cognitive fog, its calming effects might improve overall tolerability of GLP-1 therapy. However, combining multiple peptides raises questions about interactions and long-term safety that are entirely unresolved.
Other peptides like Pinealon and MOTS-c have been studied in the context of cognitive aging and metabolic regulation, respectively. Pinealon, a short peptide, has shown some promise in models of age-related cognitive decline, as noted in the P21 and Pinealon synergy for age-related cognitive decline article. Whether such synergy extends to GLP-1-related fog is speculative. MOTS-c, a mitochondrial-derived peptide, might influence metabolic parameters but has not been directly tested in alcohol craving paradigms. The peptide landscape is broad, but for the specific intersection of GLP-1, alcohol craving, and cognitive fog in veterans, P21 remains the most directly relevant candidate based on its neurotrophic profile.
Translational gaps and future directions
The leap from rodent studies to veteran populations is vast. Most P21 research has been conducted in models of acute injury or chronic neurodegeneration, not in the context of medication-induced cognitive side effects. Dosing, duration, and outcome measures are all unsettled. A 2024 commentary in Alzheimer's & Dementia by Petersen and colleagues cautioned against overinterpreting preclinical neurotrophin data, noting that many compounds that look promising in animals fail to show efficacy in human trials. For veterans, the stakes are high: AUD is a leading cause of morbidity, and any intervention that could safely reduce craving while preserving or enhancing cognition would be valuable. But the evidence base is simply not there yet.
What is needed are well-designed clinical trials that enroll veterans with AUD who are initiating GLP-1 therapy, randomising them to adjunctive P21 or placebo, and measuring both craving and cognitive outcomes over at least 12 weeks. Such trials would need to account for the heterogeneity of the veteran population, age, TBI history, psychiatric comorbidities, and use validated instruments like the Alcohol Craving Questionnaire and the Montreal Cognitive Assessment. Until then, we are left with mechanistic plausibility and a handful of encouraging but preliminary findings. Mentions of brand or product names are for identification only and do not constitute endorsement.
Common questions
What is P21 and how might it help with alcohol craving?
P21 is a peptide derived from ciliary neurotrophic factor (CNTF) that has shown neuroprotective and pro-cognitive effects in animal studies. It is not a direct treatment for alcohol craving. The hypothesis is that by enhancing neuroplasticity in prefrontal and limbic circuits, P21 might indirectly support craving reduction, particularly when combined with GLP-1 agonists. However, this has not been tested in human trials for alcohol use disorder, and any cognitive benefits are still under investigation.
Are GLP-1 agonists approved for alcohol use disorder in veterans?
No. GLP-1 receptor agonists like semaglutide are approved for type 2 diabetes and weight management, not for alcohol use disorder. Their effects on alcohol craving have been observed in some studies and anecdotal reports, but they are not an FDA-approved treatment for AUD. Veterans should only use such medications under the supervision of a healthcare provider and for approved indications.
Can P21 reverse cognitive fog caused by GLP-1 medications?
There is no published evidence that P21 can reverse GLP-1-related cognitive fog in humans. Preclinical studies suggest P21 may improve memory and learning, but these were not conducted in the context of GLP-1-induced cognitive side effects. The VA is exploring this question in early-phase research, but results are not yet available. Any use of P21 for this purpose would be experimental and should be approached with caution.
Is P21 safe for veterans with a history of traumatic brain injury?
Safety data for P21 in humans are limited. Animal studies have not shown significant toxicity, but long-term effects are unknown. Veterans with a history of TBI may have altered blood-brain barrier permeability and neuroinflammatory profiles that could affect peptide safety and efficacy. No specific studies have evaluated P21 in TBI populations, so any consideration would need to be carefully weighed against potential risks.
How does Selank compare to P21 for cognitive and craving effects?
Selank is primarily an anxiolytic peptide that may reduce stress-induced alcohol craving, while P21 is a neurotrophic peptide aimed at enhancing cognitive function. They work through different mechanisms and have not been directly compared in clinical studies. Selank's effects on cognition are less pronounced, and its role in GLP-1-related fog is unexplored. Combining them would be purely speculative and not supported by evidence.